• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.

作者信息

Bissada N K, Kaczmarek A T

机构信息

Department of Urology, Medical University of South Carolina, Charleston, USA.

出版信息

J Urol. 1995 Jun;153(6):1944-5.

PMID:7752364
Abstract

The phenomenon of regression of adenocarcinoma of the prostate after the withdrawal of antiandrogens is well documented. However, to our knowledge we report the first case of durable complete remission of hormone refractory prostate cancer after cessation of diethylstilbestrol. The drug was discontinued because the patient had disease progression while on diethylstilbestrol and withdrawal resulted in durable remission. In more than 3 years of followup since discontinuing diethylstilbestrol there has been no evidence of clinical or biochemical recurrence.

摘要

相似文献

1
Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol.
J Urol. 1995 Jun;153(6):1944-5.
2
Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.VP16与磷雌酚联合治疗激素难治性前列腺癌的抗癌作用。
Am J Clin Oncol. 2008 Apr;31(2):188-94. doi: 10.1097/COC.0b013e3181595af6.
3
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.口服雌莫司汀联合口服依托泊苷治疗激素难治性前列腺癌患者:一项为期5年随访的II期研究
Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003.
4
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.己烯雌酚与多西他赛:转移性雄激素非依赖性前列腺癌患者中微管活性剂的II期研究。
Cancer. 2007 Sep 1;110(5):996-1002. doi: 10.1002/cncr.22917.
5
Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.激素难治性前列腺癌患者停用磷酸雌莫司汀后前列腺特异性抗原急剧下降。
Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.
6
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.紫杉醇、雌莫司汀和依托泊苷治疗激素难治性前列腺癌。
Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77.
7
Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.体重指数对永久性前列腺近距离放射治疗后生化结果的影响。
Urology. 2005 Jan;65(1):95-100. doi: 10.1016/j.urology.2004.08.044.
8
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.血清前列腺特异性抗原在氟他胺撤药后降低的雄激素非依赖性前列腺癌患者的特征分析
J Urol. 1996 Feb;155(2):620-3.
9
A case of prostate cancer with a large abdominal mass effectively treated with a high dose of diethylstilbestrol-diphosphate.
Hinyokika Kiyo. 1993 Sep;39(9):849-51.
10
Oral estramustine and oral etoposide for hormone-refractory prostate cancer.口服雌莫司汀和口服依托泊苷治疗激素难治性前列腺癌。
Urology. 1997 Nov;50(5):754-8. doi: 10.1016/S0090-4295(97)00323-3.

引用本文的文献

1
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.去势抵抗性前列腺癌的激素药物转换和停药。
Nat Rev Urol. 2015 Jan;12(1):37-47. doi: 10.1038/nrurol.2014.345.
2
Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.通过肽筛选和 X 射线结构分析鉴定一种新的雄激素受体(AR)共调节剂 BUD31 和相关肽,以抑制野生型和突变型 AR 介导的前列腺癌生长。
Mol Oncol. 2014 Dec;8(8):1575-87. doi: 10.1016/j.molonc.2014.06.009. Epub 2014 Jun 24.
3
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
多西他赛化疗对转移性去势抵抗性前列腺癌产生晚期、完全且持久反应:一例病例报告
J Med Case Rep. 2014 Apr 9;8:122. doi: 10.1186/1752-1947-8-122.
4
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).去势抵抗性前列腺癌的抗雄激素撤药治疗:一项西南肿瘤协作组试验(SWOG 9426)
Cancer. 2008 Jun;112(11):2393-400. doi: 10.1002/cncr.23473.
5
Secondary hormonal manipulations in prostate cancer.前列腺癌的二线激素治疗
Curr Oncol Rep. 2005 May;7(3):228-33. doi: 10.1007/s11912-005-0078-x.
6
Secondary hormonal manipulation of prostate cancer.
Curr Urol Rep. 2001 Jun;2(3):224-30. doi: 10.1007/s11934-001-0083-z.
7
Treatment options in hormone-refractory prostate cancer: current and future approaches.激素难治性前列腺癌的治疗选择:当前与未来的方法
Drugs. 2001;61(15):2177-92. doi: 10.2165/00003495-200161150-00003.
8
Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.与前列腺癌治疗相关的抗雄激素撤药综合征:发生率及临床意义。
Drug Saf. 2000 Nov;23(5):381-90. doi: 10.2165/00002018-200023050-00003.
9
From estrogen to androgen receptor: a new pathway for sex hormones in prostate.从雌激素到雄激素受体:前列腺中激素的新通路
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5527-32. doi: 10.1073/pnas.95.10.5527.
10
The antiandrogen withdrawal syndrome.抗雄激素撤药综合征。
Urol Res. 1997;25 Suppl 2:S67-71. doi: 10.1007/BF00941991.